Planetary health and pharmacology: Addressing the ecological impact and circular threat of pharmaceuticals.
TL;DR
A mechanistic analysis of pharmaceutical ecotoxicity demonstrates that effective intervention requires targeting root causes across the pharmaceutical lifecycle rather than relying on end-of-pipe remediation, and that integrating environmental sustainability into pharmaceutical safety assessment is essential for protecting both ecological and human health.
Abstract
Drug safety science has expanded beyond patient-level pharmacovigilance to address the environmental consequences of pharmaceutical use. Pharmaceuticals are now detected across diverse ecosystems, but traditional single-compound, high-dose toxicological frameworks remain inadequate for evaluating chronic, low-dose, multi-compound environmental exposures. This review provides a mechanistic analysis of pharmaceutical ecotoxicity, tracing how molecular interactions with conserved biological targets in non-target organisms translate into population-level ecological effects. Synthetic estrogens activate nuclear hormone receptors at nanogram-per-liter concentrations, driving reproductive failure through receptor-mediated transcriptional reprogramming. Psychoactive drugs disrupt neurotransmitter systems conserved across vertebrates, altering predator avoidance and reproductive behavior at sub-microgram-per-liter levels. Anti-inflammatory drugs cause species-specific toxicity through differential phase II metabolism, as the diclofenac-vulture crisis demonstrates. Anticancer agents produce genotoxic effects in aquatic organisms through the same DNA-damaging mechanisms underlying their therapeutic activity. A unifying theme emerges when these endpoints are considered alongside antimicrobial resistance: sub-inhibitory antibiotic concentrations in environmental hotspots select for resistant bacteria and accelerate horizontal gene transfer, with resistance genes returning to human pathogens through water, food, and occupational exposure, completing a circular threat linking environmental contamination to clinical treatment failure. Mitigation strategies are evaluated across the pharmaceutical lifecycle, including biodegradable molecular design, manufacturing discharge controls, antimicrobial stewardship, and advanced wastewater treatment. The analysis demonstrates that effective intervention requires targeting root causes across the pharmaceutical lifecycle rather than relying on end-of-pipe remediation, and that integrating environmental sustainability into pharmaceutical safety assessment is essential for protecting both ecological and human health.